Molecure

Molecure S.A. is a clinical-stage biotechnology company that uses medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate underexplored protein targets to treat multiple incurable diseases. Its headquarters and laboratories are located in Warsaw, with additional laboratories in Lodz. The company is listed on the Warsaw Stock Exchange under the ticker MOC. Its most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for interstitial lung diseases such as sarcoidosis and idiopathic pulmonary fibrosis, which entered a Phase II trial in patients with sarcoidosis in March 2024. Its second proprietary candidate is OATD-02, an oral, potent and selective first-in-class dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, at the Phase I clinical development stage. On 28 March 2022, OncoArendi changed its name to Molecure.

On 28 March 2022, OncoArendi changed its name to Molecure. Molecure is a clinical-stage biotechnology company that discovers and develops first-in-class small molecule drug candidates. Its most advanced in-house candidate, OATD-01, entered a Phase II trial in patients with sarcoidosis in March 2024. Its second proprietary candidate, OATD-02, is at the Phase I clinical development stage. The company is headquartered in Warsaw with additional laboratories in Lodz, and is listed on the Warsaw Stock Exchange under the ticker MOC.

Clinical-stage biotechnology company developing first-in-class small molecule drugs for diseases with significant clinical need.

• OATD-01

  First-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis

• OATD-02

  Oral, potent and selective first-in-class dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer

1. 1Molecuremolecure.com
2. 2About: Molecuremolecure.com
3. 3Molecure SA (Poland)wikidata.org